Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 1:252:117594.
doi: 10.1016/j.lfs.2020.117594. Epub 2020 Apr 16.

Tuberculosis vaccine: A journey from BCG to present

Samreen Fatima  1 , Anjna Kumari  2 , Gobardhan Das  1 , Ved Prakash Dwivedi  3
Affiliations
Review

Tuberculosis vaccine: A journey from BCG to present

Samreen Fatima et al. Life Sci. .

Abstract

Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.

Keywords: BCG; Cytokines; Memory cells; Mycobacterium tuberculosis; T helper cells; Vaccine.

PubMed Disclaimer